Barr Labs, DuPont Pharma Form Alliance.(Brief Article)

Chemical Market Reporter, January, 2000

BARR LABORATORIES INC. and DuPont Pharmaceuticals Company have signed a letter of intent to create a broad strategic relationship to develop, market and promote five different proprietary products. DuPont will invest up to $45 million in developing three Barr proprietary products in exchange for royalties on those products and rights to acquire Barr stock.

DuPont will also perform the marketing of Barr's first proprietary product and may assist in the marketing of other Barr proprietary products. Upon finalization of the agreement, Barr and DuPont have agreed to terminate all litigation between the two companies. Barr and DuPont have been involved in ongoing litigation over Coumadin (warfarin), DuPont's leading anti-coagulant, with Barr alleging...

Premium Content Partnership | HighBeam Research provides an in-depth online archive library of reference works. HighBeam Research

 

BNET TalkbackShare your ideas and expertise on this topic

Please add your comment:

  1. You are currently: a Guest |
  2.  

Basic HTML tags that work in comments are: bold (<b></b>), italic (<i></i>), underline (<u></u>), and hyperlink (<a href></a)

advertisement
advertisement
  • Click Here
  • Click Here
  • Click Here
advertisement